Printer Friendly

IMCERA'S MALLINCKRODT MEDICAL UNIT, LIEBEL-FLARSHEIM SIGN AGREEMENT TO MAKE ULTRAJECT PREFILLED SYRINGE COMPATIBLE FOR POWER INJECTORS

IMCERA'S MALLINCKRODT MEDICAL UNIT, LIEBEL-FLARSHEIM SIGN AGREEMENT TO
 MAKE ULTRAJECT PREFILLED SYRINGE COMPATIBLE FOR POWER INJECTORS
 NORTHBROOK, Ill., Feb. 5 /PRNewswire/ -- IMCERA Group Inc. (NYSE: IMA) announced today that its Mallinckrodt Medical unit of St. Louis will soon have its Ultraject(R) prefilled syringe compatible for use with Liebel-Flarsheim power injectors, providing a significant time savings in the delivery of X-ray contrast media during radiology and cardiology imaging procedures.
 Liebel-Flarsheim will modify its current Angiomat power injector systems to accommodate both the 125ml Ultraject prefilled syringe, and the Liebel-Flarsheim 150ml empty syringe. When introduced in the United States this spring, the modified Angiomat CT will be the first CT injector in the industry capable of being used with the advanced Ultraject delivery system. The agreement will be expanded on a worldwide basis as Ultraject is introduced in Europe, Canada, South America, Latin America and Japan.
 Ultraject is a plastic syringe that is prefilled with a single dose of contrast medium. An industry first, it is designed to provide greater efficiency and minimize the risk of contamination when preparing the sterile contrast agents for patient injection.
 The modified Liebel-Flarsheim power injectors are designed for use in radiology and cardiology angiographic procedures, as well as in radiology labs for CT diagnostic studies. Of the estimated 7 million CT scans performed in the United States each year, about one-half involve power injectors and the number is growing.
 "This represents the first alliance between a contrast media producer and a power injector company to provide improved products and services to the radiology and cardiology communities," said William J. Mercer, group vice president of medical imaging for Mallinckrodt Medical. "Ultraject provides greater convenience and safety while minimizing waste. Because the syringe is prefilled with a unit dose, it eliminates the need to transfer contrast medium from glass vials to empty syringes."
 "We view this cooperative relationship as a definite benefit to the diagnostic imaging marketplace," said Edward J. Shaw, vice president and Angiomat/CT division general manager for Liebel-Flarsheim. "The Angiomat series of digital injection systems is the largest selling injector worldwide, providing a unique array of clinical benefits. Accommodation of the Ultraject prefilled syringes clearly enhances the clinical flexibility of the Angiomat, and allows it to be tailored to fit the diverse needs of contrast delivery."
 The Ultraject power injector syringe will be offered with a variety of Mallinckrodt Medical contrast agents, including Optiray(R) (ioversol), the first low osmolar, non-ionic agent developed, patented, produced and marketed by a U.S. pharmaceutical company; Hexabrix (ioxaglate meglumine 39.3 percent and ioxaglate sodium 19.6 percent injection), which is the only ionic agent available in the low osmolality class of contrast media; Conray (iothalamate meglumine injection U.S.P. 60 percent), the number-one selling conventional medium;and MD-76 (diatrizoate meglumine and diatrizoate sodium injection U.S.P.).
 Mallinckrodt Medical also offers a hand-held version of Ultraject which is available in 30ml and 50ml syringe sizes.
 Mallinckrodt Medical, with fiscal 1991 net sales and operating earnings of $513 million and $87 million, respectively, is a world leader in providing products for radiology, cardiology, nuclear medicine, anesthesiology and critical care procedures.
 IMCERA, a Fortune 300 company with net sales of more than $1.6 billion in fiscal 1991, has two other international, technology-based businesses -- Mallinckrodt Specialty Chemicals of Chesterfield, Mo., and Pitman-Moore of Lake Forest, Ill.
 Liebel-Flarsheim is a global leader in the manufacture and sale of power injectors, urology tables/X-ray systems and X-ray components. The company is currently celebrating its 75th year of service to the medical community.
 Note: Hexabrix is licensed by Guerbet, S.A. Registered U.S. Patent and Trademark office.
 -0- 2/5/92
 /CONTACT: Dave Prichard of IMCERA, 708-205-2270, or Dave Cagle of Liebel-Flarsheim, 800-347-9730/
 (IMA) CO: IMCERA Group Inc.; Liebel-Flarsheim ST: Illinois IN: MTC SU:


CK -- NY039 -- 7163 02/05/92 11:58 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Feb 5, 1992
Words:644
Previous Article:STRATEGIC DEFENSE INITIATIVE ORGANIZATION ANNOUNCES INTENTION TO PREPARE PROGRAMMATIC ENVIRONMENTAL IMPACT STATEMENT
Next Article:NEW APPOINTMENT AT FIBRONICS
Topics:


Related Articles
IMCERA'S MALLINCKRODT MEDICAL UNIT CLOSES AGREEMENT WITH SYNCOR TO DISTRIBUTE TECHNESCAN MAG3 RENAL IMAGING AGENT
MALLINCKRODT INTRODUCES OPTIRAY(R) IN ULTRAJECT(R) SYRINGES IN JAPAN, WORLD'S SECOND LARGEST MEDICAL IMAGING MARKET
Mallinckrodt, Premier Sign New Extended Agreement Covering Additional Products.
Mallinckrodt, Premier Sign New Agreement for the WarmTouch(R) Convective Warming System.
Mallinckrodt Launches New Optistar(TM) MR Contrast Delivery System in United States Following FDA Approval.
Summary Determination Granted to Mallinckrodt, Liebel-Flarsheim, and Nemoto Kyorindo.
Mallinckrodt Announces FDA Approval for Power Injection of OPTIMARK(R) MRI Agent.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters